PCI Biotech: Invitation to first-half year 2022 results presentation
26 Agosto 2022 - 04:34AM
PCI Biotech: Invitation to first-half year 2022 results
presentation
Oslo, Norway, 26 August 2022 - PCI Biotech (OSE:
PCIB) invites to an online presentation of the company's first-half
year 2022 interim report on Wednesday 31 August 2022, 08:30am –
09:30am CEST (local time).
The presentation will be held as a live webcast
and can be accessed through www.pcibiotech.com. There will be a
Q&A session at the end of the presentation and it will be
possible to post written questions through the webcast console or
through a teleconference facilitated for attendees intending to ask
questions verbally during the Q&A session.
PCI Biotech’s first-half year 2022 interim
report will be released on 31 August 2022 at 07.00 CEST. The
interim report and presentation will be made available on
www.newsweb.no and on the company's webpage,
www.pcibiotech.com.
For further information, please contact:Ronny
Skuggedal, Interim CEO / CFOEmail: rs@pcibiotech.noMobile: +47 9400
5757
About PCI
Biotech PCI
Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer
through its innovative photochemical internalisation (PCI)
technology platform. PCI induces triggered endosomal release that
is used to unlock the true potential of therapeutic modalities.
The fimaVacc
programme aims to enhance immunotherapy in cancer, by triggered
endosomal release of antigens or nucleic acids encoding antigens,
or immunostimulatory factors. In the
fimaNAc programme endosomal
release is utilised to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one
of the major bottlenecks facing this emerging and promising
field.
For further information, please visit:
www.pcibiotech.com Contact
information: PCI Biotech Holding ASA, Ullernchausséen 64,
N-0379
Oslo
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024